Key result
Renal failure and transplantation altered the distribution of rocuronium bromide, resulting in a greater volume of distribution (264 vs 207 ml/kg) and longer elimination half-life (97.2 vs 70.9 min).
Why the study?
Does end-stage renal disease alter the pharmacokinetics of rocuronium bromide compared to healthy controls?
Observational (n=20)
Does end-stage renal disease alter the pharmacokinetics of rocuronium bromide compared to healthy controls?
Renal failure and transplantation alter the distribution and prolong the elimination half-life of rocuronium, but do not affect its clearance.
No takes yet. Share an insight, caveat, or question.
May warrant cautious dosing or monitoring in ESRD; leaves open whether PK changes prolong clinical neuromuscular blockade.
Szenohradszky et al. (1992) conducted an observational in End-stage renal disease (n=20). Rocuronium bromide (ORG 9426) vs. Healthy patients undergoing elective minor surgery was evaluated on Pharmacokinetic parameters including total plasma clearance, volume of distribution, and elimination half-life. Renal failure and transplantation altered the distribution of rocuronium bromide, resulting in a greater volume of distribution (264 vs 207 ml/kg) and longer elimination half-life (97.2 vs 70.9 min).